Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

-1.12 (-0.80%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
927,988 shs
Average Volume
850,986 shs
Market Capitalization
$13.83 billion
P/E Ratio
Dividend Yield
Price Target

Neurocrine Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
2.5% Upside
$142.38 Price Target
Short Interest
2.44% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.49mentions of Neurocrine Biosciences in the last 14 days
Based on 32 Articles This Week
Insider Trading
Selling Shares
$25.81 M Sold Last Quarter
Proj. Earnings Growth
From $4.84 to $6.35 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

98th out of 909 stocks

Biological Products, Except Diagnostic Industry

11th out of 156 stocks

NBIX stock logo

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock Price History

NBIX Stock News Headlines

The 5 Stocks Most Sold By Insiders This Year (NBIX)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Wall Street Analysts Are Neutral on Top Healthcare Picks
3 Red-Hot Biotech Rockets Blasting Off in 2024
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
10 Best Performing Biotech ETFs in 2024
Neurocrine begins phase 2 trial for depression drug
Wells Fargo Reaffirms Their Hold Rating on Neurocrine (NBIX)
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
23 Analysts


Net Income
$249.70 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$2.68 per share
Book Value
$22.72 per share


Free Float
Market Cap
$13.83 billion
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 66)
    CEO & Director
    Comp: $1.9M
  • Mr. Matthew C. Abernethy (Age 43)
    Chief Financial Officer
    Comp: $1.04M
  • Mr. Darin M. Lippoldt Esq. (Age 58)
    Chief Legal Officer & Corporate Secretary
    Comp: $921.01k
  • Mr. Kyle W. Gano Ph.D. (Age 51)
    Chief Business Development & Strategy Officer
    Comp: $921.52k
  • Dr. Eiry Wyn Roberts M.D. (Age 59)
    Chief Medical Officer
    Comp: $1.04M
  • Dr. Jude Onyia Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $621.66k
  • Jane Sorensen
    Head of Investor Relations
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 58)
    Chief Human Resources Officer
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 59)
    Chief Commercial Officer
    Comp: $805k
  • Mr. David Warren Boyer (Age 44)
    Chief Corporate Affairs Officer

NBIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price target for 2024?

23 Wall Street analysts have issued 1 year target prices for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $200.00. On average, they predict the company's stock price to reach $142.38 in the next year. This suggests a possible upside of 2.5% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2024?

Neurocrine Biosciences' stock was trading at $131.76 at the beginning of the year. Since then, NBIX stock has increased by 5.5% and is now trading at $138.97.
View the best growth stocks for 2024 here

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NBIX earnings forecast

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its earnings results on Wednesday, February, 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 12.85% and a net margin of 13.23%. The business's revenue was up 25.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.88 EPS.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.51%), Assenagon Asset Management S.A. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Los Angeles Capital Management LLC (0.25%), Rice Hall James & Associates LLC (0.13%) and Portman Square Capital LLP (0.00%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBIX) was last updated on 4/24/2024 by Staff

From Our Partners